Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Novo Nordisk has stopped two trials of a drug that aims to tame inflammation as a way to improve cardiovascular health, another blow for the approach. The company said it had halted the … [Read more…]
Pfizer said Friday it’s suing Novo Nordisk and obesity biotech Metsera, a day after Novo set off a bidding war against Pfizer to acquire Metsera. A month ago, Pfizer said that it would acquire Metsera for $4.9 billion. But Novo on Thursday launched a takeover bid valuing the biotech at around $6 billion, triggering a … [Read more…]
Novo Nordisk’s obesity drug Wegovy was cleared by U.S. regulators on Friday to treat an increasingly common liver disease, adding to the list of conditions for which the blockbuster therapy is now approved. The Food and Drug Administration granted accelerated approval to Wegovy for patients with metabolic dysfunction-associated steatohepatitis, or MASH, with moderate to advanced … [Read more…]
CHICAGO — Late-stage results of Novo Nordisk’s obesity candidate CagriSema suggest the drug is comparable to Eli Lilly’s Zepbound on safety and efficacy, further data indicating that CagriSema may not be the standout treatment that investors had hoped for. Novo previously reported that patients on CagriSema lost 20% of their weight in a 68-week Phase … [Read more…]
In the late 2010s, scientists at the Danish drugmaker Novo Nordisk developed a new weekly obesity treatment that targeted three hormones at once. In mice studies, the drug, which activated receptors of the GLP-1, GIP, and glucagon hormones, caused notable weight loss. But Novo shelved the therapy. The company was concerned about potential side effects … [Read more…]